KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study

•At least 11% of Danish advanced NSCLC patients harbored a KRAS G12C mutation.•More KRAS G12C patients had PD-L1 expression level ≥50% than other NSCLC patients.•Survival was longer for PD-L1 expression of ≥50% compared to

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2023-04, Vol.178, p.172-182
Main Authors: Frost, Matilde Grupe, Jensen, Kristoffer Jarlov, Gotfredsen, Ditte Resendal, Sørensen, Anne Mette Skov, Ankarfeldt, Mikkel Zöllner, Louie, Karly S., Sroczynski, Nicholas, Jakobsen, Erik, Andersen, Jon Lykkegaard, Jimenez-Solem, Espen, Petersen, Tonny Studsgaard
Format: Article
Language:English
Subjects:
Adult
B7-H1 Antigen - metabolism
Carcinoma, Non-Small-Cell Lung - epidemiology
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - therapy
Denmark - epidemiology
Female
Humans
Kirsten Rat Sarcoma viral Oncogene homolog DNA with G12C mutation at the protein level (KRAS G12C mutation)
KRAS mutation
Lung Neoplasms - genetics
Lung Neoplasms - metabolism
Lung Neoplasms - therapy
Male
Mutation
Non-Small Cell Lung Cancer (NSCLC)
Overall survival
Programmed Death Ligand 1 (PD-L1) expression
Proto-Oncogene Proteins p21(ras) - genetics
Proto-Oncogene Proteins p21(ras) - metabolism
Real world evidence
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•At least 11% of Danish advanced NSCLC patients harbored a KRAS G12C mutation.•More KRAS G12C patients had PD-L1 expression level ≥50% than other NSCLC patients.•Survival was longer for PD-L1 expression of ≥50% compared to
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2023.02.021